Medpace Faces Class Action Lawsuit Following 16% Stock Plunge

2026-05-10 companies

New York, Saturday, 9 May 2026.
After a 16% stock plummet, law firms are urging Medpace investors to join a class action lawsuit before June 8 over allegedly inflated 2025 financial forecasts.

Unpacking the Financial Miss

Multiple investor rights law firms have mobilized against clinical research organization Medpace Holdings, Inc. (NASDAQ: MEDP), filing securities fraud class action lawsuits on behalf of shareholders [1][2][4]. The litigation, centralized under the caption Durbin v. Medpace Holdings Inc. in the U.S. District Court for the Southern District of Ohio, centers on allegations that the company violated the Securities Exchange Act of 1934 by artificially inflating its financial forecasts [2][6]. Central to the dispute is the “Class Period,” spanning from April 22, 2025, to February 9, 2026 [1][2][4]. During this timeframe, Medpace management repeatedly projected a highly optimistic book-to-bill ratio of 1.15 for the fourth quarter of 2025 [3][4][8]. However, when the company released its Q4 2025 earnings on February 9, 2026, the actual book-to-bill ratio materialized at just 1.04, falling significantly short of guidance [2][4][6].

Compounding Challenges and Legal Deadlines

The financial turbulence for Medpace has extended well beyond the initial February 2026 shockwave. Investigations by legal counsel, including Bleichmar Fonti & Auld LLP, suggest that the company’s fundamental metrics continued to deteriorate into the new year [6]. Reports indicate that cancellations kept climbing, driving the book-to-bill ratio down to a troubling 0.88 for the first quarter of 2026 [6]. Compounding the operational struggles, Medpace’s President, Jesse Geiger, has announced his intention to step down from his position [6]. As these compounding factors entered the public domain, the company’s stock experienced another brutal hit, declining roughly 23% during afternoon trading on April 23, 2026 [6].

Sources

Securities litigation Medpace Holdings